![EMJ Hematology 9 [Supplement 1] 2021 - front cover](https://www.emjreviews.com/wp-content/uploads/2021/04/EMJ-Hematology-9-Supplement-1-2021-front-cover.jpg)
This review provides a summary of presentations from the 2020 virtual European Hematology Association (EHA)-Scientific Working Group (SWG) Scientific Meeting on Immunotherapy for Hematological Disorders. The session focussed on the T-cell Ig and mucin domain containing protein-3 (TIM-3) receptor and its potential as a new target for drug development in the treatment of patients with higher-risk myelodysplastic syndrome (MDS).
Latest articles
All articles
9 Mins
14th
August
Recent Advancements in wAIHA
AIHA is an acquired, heterogeneous group of rare diseases with a prevalence of 17 per 100,000.1 This group includes wAIHA…
Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content.
3 Mins
25th
July
Filgrastim Prophylaxis for Neutropenia in Myelodysplasia Pre-Surgery: Case Report
Myelodysplastic syndromes are a group of disorders that affect the bone marrow, subsequently affecting the growth and relative…
Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content.